🔍

ALKEM - Alkem Lab

📊 NSE: ALKEM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:08

📢 Recent Corporate Announcements

Alkem Labs Receives ₹333.38 Cr Income Tax Order; No Immediate Cash Outflow

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 24 Apr 2026, 04:42 PM

Alkem Laboratories has received an assessment order for AY 2023-24 from the Income Tax Department with a disputed tax amount of ₹333.38 Crores. The order involves disallowances related to Section 80IE deductions and transfer pricing adjustments. Importantly, the company has clarified that there is no immediate cash outflow required as the demand will be adjusted against available MAT credits. Alkem intends to contest the order through an appeal, asserting that the claims are not legally tenable.

Income Tax authority issued an order for AY 2023-24 with a disputed amount of ₹333.38 Crores.
Dispute stems from partial disallowance of Section 80IE deductions and transfer pricing adjustments.
No immediate cash impact on the company due to the utilization of available MAT credits.
Alkem Laboratories plans to file an appeal against the order, citing strong factual and legal grounds.

💡 Investors should monitor the outcome of the appeal process as a favorable ruling would preserve MAT credits for future tax liabilities. No immediate impact on liquidity or operations is expected.

Alkem Laboratories CEO Dr. Vikas Gupta Resigns; Transition to Continue Until June 30, 2026

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 24 Apr 2026, 02:33 PM

Alkem Laboratories has announced the resignation of its Chief Executive Officer, Dr. Vikas Gupta, effective June 30, 2026. Dr. Gupta is stepping down to pursue new professional opportunities after serving as a Key Managerial Personnel. The company has established a transition period of approximately two months to ensure operational continuity. Investors will be closely watching for the announcement of a successor to lead the pharmaceutical major.

Dr. Vikas Gupta resigned as CEO and Key Managerial Personnel on April 24, 2026.
The executive will continue in his current role until June 30, 2026, for a smooth transition.
The resignation is intended to allow the outgoing CEO to pursue other professional opportunities.
The company has not yet named a successor to the CEO position in this disclosure.

💡 Investors should monitor upcoming board meetings for the appointment of a new CEO to gauge future strategic direction. Maintain a watch on the stock for any volatility resulting from leadership uncertainty during the transition period.

Alkem Laboratories Files Revised XBRL Financial Results Following NSE Clarification

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 10 Apr 2026, 06:02 PM

Alkem Laboratories has responded to a clarification sought by the National Stock Exchange (NSE) regarding its financial results for the quarter ended March 31, 2025. The exchange pointed out discrepancies in the XBRL filing where the company had incorrectly categorized certain quarter-end figures. In response, the company has submitted revised Standalone and Consolidated XBRL filings to rectify these technical errors. This update is administrative and does not impact the previously reported financial figures or the company's fundamental performance.

NSE sought clarification on June 26, 2025, regarding discrepancies in XBRL financial submissions.
The issue pertained to the labeling of audited financial results for the quarter ended March 31, 2025.
Alkem has submitted revised Standalone and Consolidated XBRL files to the exchange on July 1, 2025.
The clarification was made in compliance with Regulation 33 of SEBI (LODR) Regulations, 2015.

💡 Investors should treat this as a routine regulatory correction with no impact on the company's valuation or operations. No specific action is required.

Alkem Labs Doubles Investment to INR 1,036 Crores for New Ujjain Manufacturing Facility

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 02 Apr 2026, 12:59 PM

Alkem Laboratories has announced a significant upward revision in its capital expenditure for a new greenfield formulations plant in Ujjain, Madhya Pradesh. The Board of Directors has approved increasing the investment from the previously planned INR 533 crores to INR 1,036 crores. This investment will be deployed in a phased manner on a 30-acre land parcel. The doubling of the budget suggests a larger scale of operations or more advanced technology integration than initially planned.

Investment for Ujjain facility increased from INR 533 crores to INR 1,036 crores
Setting up a greenfield formulations manufacturing facility on 30 acres of land
Land allotted by DMIC Vikram Udyogpuri Limited in Phase-2, Ujjain
Capital deployment to be executed in a phased manner
Expansion follows the initial land allotment approval dated March 18, 2026

💡 Investors should view this as a strong signal of long-term growth and capacity building. Monitor future management commentary regarding the expected timeline for commissioning and the specific therapeutic segments this facility will serve.

Alkem Laboratories Announces Senior Management Changes and Reporting Oversight

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 31 Mar 2026, 06:46 PM

Alkem Laboratories has informed the exchanges regarding the cessation of two senior management personnel. Mr. Ravinder Chaklam retired from the company effective March 24, 2026, following his superannuation. Additionally, Mr. Mukesh Tiwari transitioned to a role within a wholly-owned subsidiary, ceasing his senior management position in the parent entity as of October 1, 2025. The company noted that the delay in filing these disclosures was due to an inadvertent administrative oversight.

Mr. Ravinder Chaklam ceased to be a Senior Management Personnel effective March 24, 2026, due to retirement.
Mr. Mukesh Tiwari moved to a wholly-owned subsidiary, ending his SMP role in the parent company effective October 1, 2025.
The company acknowledged a reporting delay for these changes, citing an unintentional oversight.
Disclosures were made under Regulation 30 of SEBI LODR Regulations 2015.

💡 These changes appear to be routine retirements and internal transfers rather than distress-led exits. No immediate action is required, though investors should monitor for any further delays in regulatory filings.

Alkem Laboratories Sets Up UAE Subsidiary with AED 3.67 Million Capital

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 30 Mar 2026, 05:36 PM

Alkem Laboratories has incorporated a wholly owned subsidiary, Alkem Pharmaceuticals Scientific Office FZ LLC, in Dubai Healthcare City, UAE. The new entity has a subscribed capital of AED 3.67 million and is designed to focus on product manufacturing and obtaining registrations in the region. While the incorporation is complete, the company noted that regulatory approvals from the UAE Ministry of Health are currently delayed due to regional conflict. This move aligns with Alkem's strategy to expand its regulatory and operational footprint in international markets.

Incorporation of 100% subsidiary Alkem Pharmaceuticals Scientific Office FZ LLC in Dubai Healthcare City.
Total subscribed capital of AED 3,670,000 (approx. INR 8.3 crore) consisting of 3,670 equity shares.
The subsidiary is established to undertake manufacturing and product registration activities, excluding trading.
Company reports delays in Ministry of Health and Prevention approvals due to ongoing regional geopolitical conflict.

💡 Investors should view this as a routine long-term expansion move into the Middle East market with no immediate impact on the bottom line. Monitor future updates regarding product registrations and the commencement of operations in the UAE.

Alkem Laboratories Appoints Samsher Kumar Deo as Senior Management Personnel

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 27 Mar 2026, 06:09 PM

Alkem Laboratories has announced the appointment of Mr. Samsher Kumar Deo to its senior management team, effective March 27, 2026. Mr. Deo brings over 29 years of extensive experience, particularly in strengthening sales performance within the pharmaceutical sector. He holds a B.Sc. degree from Bhagalpur University, completed in 1992. This move is part of the company's ongoing efforts to bolster its leadership and operational execution in the domestic market.

Appointment of Mr. Samsher Kumar Deo as Senior Management Personnel effective March 27, 2026.
The appointee possesses over 29 years of professional experience in handling sales functions.
Mr. Deo holds a Bachelor of Science (B.Sc.) degree from Bhagalpur University, completed in 1992.
The appointment is on a permanent basis as long as he remains in the company's employment.

💡 This is a routine senior management appointment and does not require any immediate portfolio action. Investors should monitor if the new leadership contributes to improved sales growth in future quarterly results.

Alkem Laboratories to Close Trading Window from March 30, 2026, for Q4 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 11:24 AM

Alkem Laboratories has informed the stock exchanges that its trading window for insiders will be closed starting March 30, 2026. This closure is a mandatory compliance measure under SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction is in anticipation of the upcoming financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are officially declared to the BSE and NSE.

Trading window closure begins on March 30, 2026.
Closure is related to the financial results for the quarter and year ending March 31, 2026.
Window will reopen 48 hours after the communication of results to stock exchanges.

💡 No action is required as this is a routine regulatory filing. Investors should look forward to the announcement of the actual earnings date for Q4 and FY26 performance evaluation.

Alkem Launches Semaglutide Injection in India at INR 450 per Week

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Mar 2026, 12:16 PM

Alkem Laboratories has launched indigenously-developed Semaglutide injections in India for type-2 diabetes and chronic weight management. The product is priced aggressively at INR 1,800 per month (INR 450 per week), aiming to significantly lower the entry barrier for GLP-1 therapy. The company received DCGI approval following successful Phase 3 clinical trials in India. This launch strengthens Alkem's position in the high-growth chronic therapy segment, leveraging its extensive distribution network.

Launched Semaglutide under brand names Semasize, Obesema, and Hepaglide for diabetes and weight loss
Disruptive pricing at INR 450 per week compared to significantly higher costs for imported alternatives
Received DCGI approval for manufacturing and marketing after completing Phase 3 clinical trials in India
Introduced both pre-filled disposable pens and reusable injection pens for higher maintenance doses
Targets the chronic therapy market where Alkem is currently the 6th largest player in India

💡 Investors should monitor the market share capture in the diabetes and obesity segment, as this affordable pricing could drive significant volume growth. This launch marks a major milestone in Alkem's transition toward a stronger chronic portfolio.

Alkem Labs Receives EU GMP Certificate for Daman Facility Valid for 3 Years

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 20 Mar 2026, 09:18 PM

Alkem Laboratories has received a Certificate of GMP Compliance from the Malta Medicines Authority for its manufacturing facility located in Daman, India. This certification follows a successful inspection conducted in December 2025. The certificate is valid for a period of three years, effective from December 9, 2025. This regulatory approval is a significant step as it ensures the facility meets European standards for pharmaceutical manufacturing, facilitating exports to the EU market.

Received EU GMP compliance certificate from Malta Medicines Authority for the Daman plant.
The certification is valid for a 3-year period starting from December 9, 2025.
Follows a successful inspection previously intimated on December 10, 2025.
Ensures continued access to the European Union market for products manufactured at this site.

💡 Investors should view this as a positive regulatory milestone that de-risks the company's European export business. No immediate action is required, but it reinforces confidence in Alkem's manufacturing quality standards.

Alkem Laboratories to Meet Millennium Capital Management on March 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Mar 2026, 05:08 PM

Alkem Laboratories has announced a virtual meeting with Millennium Capital Management scheduled for March 26, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates and industry trends. The meeting is being conducted in compliance with SEBI Listing Obligations and Disclosure Requirements. While no specific financial results will be discussed outside of public disclosures, such meetings are key for institutional sentiment.

Meeting scheduled with Millennium Capital Management for March 26, 2026.
The interaction will be held through a virtual platform.
The schedule is subject to change based on exigencies from either the company or the investor.
Disclosure made under relevant provisions of SEBI (LODR) Regulations, 2015.

💡 No immediate action is required as this is a routine investor interaction. Investors should watch for any subsequent investor presentations or transcripts that may be uploaded to the exchanges.

Alkem Labs to Invest ₹533 Crore in New Greenfield Formulation Facility in Ujjain

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 18 Mar 2026, 07:56 PM

Alkem Laboratories has received an allotment letter for 30 acres of land in Ujjain, Madhya Pradesh, to set up a new greenfield formulation manufacturing facility. The Board of Directors has approved a total investment of up to INR 533 crores for this project. The capital expenditure will be deployed in a phased manner to enhance the company's production capacity. This expansion is a strategic move to strengthen Alkem's domestic manufacturing footprint and support long-term growth.

Allotment of 30 acres of land in DMIC Vikram Udyogpuri Limited, Phase-2, Ujjain
Board approval for a capital investment of up to INR 533 crores
Project involves setting up a greenfield formulation manufacturing facility
Investment to be executed in a phased manner to manage capital allocation

💡 Investors should view this as a positive indicator of the company's growth trajectory and capacity expansion. Monitor the execution timeline and the impact of this capex on the company's debt-to-equity ratio and future margins.

Alkem Labs Receives EU GMP Compliance Certificate for Baddi Manufacturing Facility

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 14 Mar 2026, 03:45 PM

Alkem Laboratories has received a Certificate of GMP Compliance from the German Health Authority for its manufacturing plant located in Baddi, India. This certification follows a successful inspection conducted between November 4 and November 10, 2025. The certificate is valid for a period of three years from the date of inspection, ensuring the facility meets European standards for human medicines. This regulatory clearance is crucial for the company's ability to supply pharmaceutical products to the European market.

Received 'Certificate of GMP Compliance' from the Department of Pharmacy (Human Medicines) – Germany.
The inspection was conducted at the Baddi, India facility from 04th to 10th November 2025.
The compliance certificate is valid for a period of 3 years from the date of inspection.
The approval follows the initial inspection intimation provided by the company on 10th November 2025.

💡 Investors should view this as a positive development that de-risks the company's European export potential from the Baddi site. No immediate action is required, but this reinforces Alkem's strong regulatory compliance track record.

Alkem Labs Subsidiary Executes SPA to Acquire 51-55% Stake in Swiss Firm Occlutech Holding AG

🟢 POSITIVE ⭐ 9/10

M&A 📅 06 Mar 2026, 03:37 PM

Alkem Laboratories' subsidiary, Alkem Medtech, has officially signed a Share Purchase Agreement to acquire a controlling stake in Switzerland-based Occlutech Holding AG. The acquisition involves purchasing between 51% and 55% of the total issued equity share capital. This move follows the initial announcement made on February 13, 2026, signaling progress in Alkem's expansion into the medical technology sector. The transaction marks a significant step in Alkem's inorganic growth strategy in international markets.

Alkem Medtech to acquire a minimum of 51% and a maximum of 55% equity in Occlutech Holding AG
Occlutech Holding AG is a Swiss-incorporated company specializing in medical technology
The Share Purchase Agreement (SPA) was executed on March 06, 2026
The acquisition is being executed through Alkem's wholly-owned subsidiary, Alkem Medtech Private Limited

💡 Investors should view this as a strategic diversification into the high-growth medical devices segment. Monitor for future disclosures regarding the acquisition valuation and its impact on the company's consolidated debt and margins.

Alkem Laboratories Releases Strategic Roadmap Recording for MedTech Division

🔵 WATCH ⭐ 6/10

EXPANSION 📅 20 Feb 2026, 06:31 PM

Alkem Laboratories has officially released the video recording of its investor meet focused on the strategic way forward for Alkem MedTech. The disclosure, dated February 20, 2026, provides transparency into the company's future plans for its medical technology vertical. This meeting is significant as it outlines how the company intends to diversify beyond traditional pharmaceuticals. Investors can access the full recording via the company's website to evaluate the growth potential of this specific business segment.

Official recording of the 'Investor meet on Alkem MedTech’s strategic way forward' is now public.
The meeting focused specifically on the future growth drivers and strategy for the MedTech division.
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) 2015.
Strategic updates for the MedTech arm indicate a focus on business diversification and long-term value creation.

💡 Investors should review the recording to understand the capital allocation and revenue expectations for the MedTech business. Monitor the segment's progress as a potential catalyst for valuation rerating beyond the core pharma business.

View All ALKEM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 2.3% YoY to INR 12,964.5 Cr in FY25. Domestic formulation sales grew 7% YoY in FY25, while US sales de-grew 15% in H1FY25 due to price erosion and supply chain issues. Rest of World (ROW) sales grew 33% in FY24 and 7% in H1FY25. In Q2 FY26, total revenue reached INR 4,001 Cr, a 17.2% YoY increase.

Geographic Revenue Split

The domestic market is the primary driver, contributing 70% of total revenue (INR 9,075 Cr in FY25). The US market accounts for 22% (INR 2,852 Cr), and the Rest of the World (ROW) contributes the remaining 8-10%.

Profitability Margins

Adjusted PAT margin improved from 14.3% in FY24 to 17.1% in FY25 (INR 2,215 Cr). This improvement was driven by a better product mix and cost control measures. Return on Capital Employed (ROCE) averaged 20% between FY20-FY24 and is projected to reach ~22% by FY27.

EBITDA Margin

EBITDA margin stood at 23.0% in Q2 FY26 (INR 920.8 Cr). The PBILDT margin improved by 520 bps in H1FY25 compared to the previous year, primarily due to benign raw material prices and rationalization of the product portfolio to focus on high-margin chronic therapies.

Capital Expenditure

Planned capital expenditure for FY26 is estimated at INR 700-750 Cr. This spending is intended for capacity maintenance and expansion into new segments like biosimilars and orthopedic implants, funded primarily through internal accruals.

Credit Rating & Borrowing

Maintains a strong credit profile with ratings of CRISIL AA+/Stable/A1+ and CARE AA+; Stable / CARE A1+. Total debt as of March 31, 2025, was INR 1,381 Cr, with an overall gearing ratio of 0.11x, indicating very low reliance on external debt.

⚙️ Operational Drivers

Raw Materials

Specific names not disclosed, but raw materials, freight, and input costs are cited as major margin drivers, with 'benign' pricing contributing to a 520 bps margin improvement in H1FY25.

Capacity Expansion

Operates 19 manufacturing facilities (18 in India, 1 in the US) and 4 R&D centers. A new CDMO plant for Enzene in the US recently became operational in September 2025, with a target revenue capacity of INR 300 Cr within 12-18 months.

Raw Material Costs

Raw material costs remained benign in H1FY25, supporting margin expansion. The company uses a strategy of rationalizing its product portfolio to offset input cost volatility and focus on higher-margin products.

Manufacturing Efficiency

Focusing on 'profitable growth' by rationalizing low-margin products. ROCE is expected to remain healthy at ~22% for FY25-FY27, reflecting efficient asset utilization.

Logistics & Distribution

Distribution is managed by a field force of over 12,000 medical representatives (MRs) and 8,000 stockists to ensure demand off-take for new and existing products.

📈 Strategic Growth

Expected Growth Rate

5-8%

Growth Strategy

Growth will be achieved by outperforming the Indian pharmaceutical market by 100-150 bps through new launches in chronic therapies (diabetes, oncology, neurology). Additionally, the company is scaling its US CDMO business (Enzene) and entering the orthopedic implant market to diversify revenue streams.

Products & Services

Pharmaceutical formulations in therapeutic areas including anti-infectives, gastroenterology, pain/analgesics, anti-diabetics, cardiology, oncology, dermatology, and biosimilars.

Brand Portfolio

Alkem (Parent Brand), Enzene (Biosimilars). Specific product brand names not listed in the provided text.

New Products/Services

Launched 4 products in the US in Q2 FY26. New CDMO operations in the US are expected to contribute INR 70-80 Cr in revenue for the current fiscal year.

Market Expansion

Expanding presence in regulated and semi-regulated markets including Australia, Chile, Philippines, Kazakhstan, and Europe. Target is to increase the share of international revenue beyond the current 30%.

Market Share & Ranking

Ranked 5th in the Indian pharmaceutical market according to IQVIA MAT March 2025.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and biosimilars. Alkem is positioning itself by increasing its chronic segment sales force and investing in Enzene Bioscience to capture higher-growth biotech opportunities.

Competitive Landscape

Faces intense competition in the acute segment from other large Indian generic players, leading to pricing pressure.

Competitive Moat

Moat is built on a 50-year legacy, a dominant position in anti-infectives/gastro (Rank 5 in India), and a massive distribution network of 12,000+ MRs. This scale makes it difficult for new entrants to compete on distribution and brand recall.

Macro Economic Sensitivity

Sensitive to healthcare spending and inflation in raw material/freight costs, which impacted margins in previous years before normalizing in FY24.

Consumer Behavior

Increasing demand for chronic disease management (diabetes, heart health) is driving the company's shift in focus from acute to chronic therapies.

Geopolitical Risks

Operations in 40+ countries expose the company to changes in import/export policies and political conditions in key global markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA inspections (all sites currently have EIR) and Indian DPCO/NLEM price controls which affect ~30% of domestic revenue.

⚠️ Risk Analysis

Key Uncertainties

High dependence on the acute segment (80% of domestic sales) which is slower-growing and prone to price revisions. Regulatory risks from USFDA or Indian price control changes could impact margins by 2-3%.